Authors

Harry P. Erba, MD, PhD, University of Alabama

Latest:

Dr. Ranganath on Treatment Considerations in Nonmetastatic Prostate Cancer

Harsha Ranganath, MD, a fellow in the Division of Hematology & Oncology at the University of Tennessee West Cancer Center, discusses treatment considerations in nonmetastatic prostate cancer.

Harvard Medical School

Harvey I. Pass, MD

Latest:

Dr. Harvey I. Pass on Personalized Surgical Approaches in Lung Cancer

Harvey I. Pass, MD, director, Thoracic Surgery, Thoracic Oncology, NYU Langone Medical Center, discusses what it means to take a personalized approach to surgery in lung cancer.

Hashem El-Serag, MD, MPH

Latest:

Dr. Hashem El-Serag on the Relationship Between NASH and HCC

Hashem El-Serag, MD, MPH, medicine-gastroenterology, Baylor College of Medicine, discusses the relationship between nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC).

Hassane M. Zarour, MD

Latest:

Dr. Zarour on Unmet Needs in Melanoma

Hassane M. Zarour, MD, professor of medicine, University of Pittsburgh, discusses unmet needs in melanoma.

Hatem Soliman, MD

Latest:

Dr. Soliman the Utility of ADCs in Breast Cancer

Hatem Soliman, MD, discusses the utility of antibody-drug conjugates in breast cancer.

Hatem Soliman, MD, H. Lee Moffitt Cancer Center & Research Institute

Hatim Husain, MD

Latest:

Looking Ahead in NSCLC Oncodrivers and Targeted Therapies

Panelists discuss how ASCO 2025 highlighted exciting advances in targeted therapy including neoadjuvant approaches, dynamic biomarkers like circulating tumor DNA, mixed results with HER3-directed antibody-drug conjugates (ADCs) in the EGFR space, but promising data with trastuzumab-based ADCs, emphasizing the critical importance of comprehensive biomarker testing to ensure no patients miss potentially life-changing targeted therapies.

Haydia Haniff

Latest:

Patients Coping With Insomnia May Benefit from Behavioral Interventions

Cognitive behavioral therapy for insomnia (CBT-I) and mindfulness-based stress reduction (MBSR) can improve sleep for patients with cancer, but CBT-I continues to be the best nonpharmacologic option

Hayley Virgil

Senior Editor,

Latest:

Olaparib Plus Abiraterone/Prednisone Displays Efficacy in mCRPC

Frontline treatment with olaparib plus abiraterone/prednisone led to a PFS benefit vs olaparib or abiraterone/prednisone alone in BRCA1/2– or ATM–altered mCRPC.

Haythem Y. Ali, MD

Latest:

Dr. Ali on the Need to Understand Real-World Disparities in BRCA Testing in TNBC

Haythem Y. Ali, MD, member, Henry Ford Cancer Institute, Henry Ford Health System, discusses the need to understand real-world disparities with BRCA testing referrals and uptake in patients with triple-negative breast cancer.

He James Zhu, MD, PhD

Latest:

Dr. Zhu on Mitigating Toxicities of Elective Nodal Irradiation in Breast Cancer

He James Zhu, MD, PhD, discusses potential strategies to mitigate the toxicities of elective nodal irradiation in breast cancer.

Hearn Jay Cho, MD, PhD

Latest:

Dr. Cho on Investigational BiTE Therapies in Multiple Myeloma

Hearn Jay Cho, MD, PhD, discusses investigational bispecific T-cell engager therapies in multiple myeloma.

Latest:

Adjuvant Osimertinib in Early-Stage NSCLC: The ADAURA Trial

Advances in Testing and Targeted Therapy for NSCLC: Translating Evidence to Clinical Practice

Heather A. Wakelee, MD, FASCO

Latest:

EGFR mNSCLC: Future Directions

Panelists discuss how despite significant advances in EGFR-targeted therapy, critical unmet needs persist in EGFR-positive non–small cell lung cancer (NSCLC), including the need for better strategies to combat resistance mechanisms, more effective treatments for brain metastases, improved options for uncommon EGFR mutations, and the development of biomarker-driven approaches to optimize sequencing of available therapies.

Heather A. Wakelee, MD, Stanford University Medical Center

Latest:

Experts on the Evaluation of CEACAM5-Targeted Therapy in NSCLC

Balazs Halmos, MD, Martin F. Dietrich, MD, PhD, Roy S. Herbst, MD, PhD, Suresh S. Ramalingam, MD, FACP, FASCO, Mark Socinski, MD, and Heather Wakelee, MD, FASCO, discuss the evaluation of CEACAM5 biomarker testing in non–small cell lung cancer.